A historian recounts the odorous origins of the first evidence for molecular structure
Commentary
Advertisement
Advertisement
Advertisement
Opinion
A polemical history shines a scientific spotlight on a remarkable and long-overlooked process
When Ottoline Leyser was appointed as the chief executive of UK Research and Innovation (UKRI) in 2020, she acquired a front-row seat for some extraordinary events in United Kingdom and European politics. She took charge of UKRI—which was forged from ...
In the days since Texas federal judge Matthew J. Kacsmaryk invalidated the approval by the US Food and Drug Administration (FDA) of mifepristone, a medication used to terminate pregnancy, a shock wave of concern has swept through many people, organizations, and companies that work closely with the agency. The strong opposition reflects the high stakes not only for pregnant persons and for the FDA, but also for the scientific process of drug development and public access to safe and effective medications.
Droughts are coming on faster
The perfumer before Pasteur
Sleep like a bear
Designer bugs as cancer drugs?
The expanding family of T follicular regulatory cells
Rethink reporting of evaluation results in AI
Judicial interference with mifepristone
A boost in learning by removing nuclear phosphodiesterases and enhancing nuclear cAMP signaling